Beschreibung
Pharmacological effects
Drug for the treatment of benign prostatic hyperplasia. Dutasteride – dual inhibitor of 5α-reductase. Inhibit 5α-reductase isozymes 1 and type 2, which is responsible for converting testosterone 5 α -dihydrotestosterone (DHT). DHT androgen is the main responsible for hyperplasia of glandular prostata tissue.
The maximum effect of reducing dutasteride concentrations of DHT is dose-dependent and is observed after the start of treatment within 1-2 weeks. After 1 and 2 weeks of dutasteride dose of 500 mg / day average in serum is reduced by 85% and 90% concentrations of dihydrotestosterone.
Avodart, indications for use
As monotherapy for the treatment and prevention of the progression of benign prostatic hyperplasia by its size, reducing relief of symptoms, improves urge to urinate, reduces the risk of acute urinary retention and the need for surgical intervention.
As a combination therapy with alpha-1 blocker for the treatment and prevention of the progression of benign prostatic hyperplasia by its size, reducing symptom relief, improves urge to urinate, reduces the risk of acute urinary retention and the need for surgical intervention. Mainly I studied the combination of dutasteride and tamsulosin alpha1 blocker.
